Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C32H35F3N4O5S |
| Molecular Weight | 644.704 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCS(=O)(=O)N1CCN(CC2=CC=C(NC(=O)C3=CC=C(C=C3)C4=C(OC(F)(F)F)C=CC(NC(=O)C5CC5)=C4)C=C2)CC1
InChI
InChIKey=MAQDQJWCSSCURR-UHFFFAOYSA-N
InChI=1S/C32H35F3N4O5S/c1-2-19-45(42,43)39-17-15-38(16-18-39)21-22-3-11-26(12-4-22)36-30(40)24-7-5-23(6-8-24)28-20-27(37-31(41)25-9-10-25)13-14-29(28)44-32(33,34)35/h3-8,11-14,20,25H,2,9-10,15-19,21H2,1H3,(H,36,40)(H,37,41)
| Molecular Formula | C32H35F3N4O5S |
| Molecular Weight | 644.704 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
A-689 (AZD-7295) was the lead compound from Arrow Therapeutics' second series of hepatitis C virus (HCV) NS5a inhibitors. AZD-7295 is a selective inhibitor of HCV NS5A within vitroantiviral activity of 7nM and 1.24mM against HCV genotype1b and 1a replicons respectively, with significant liver concentrationin preclinical studies. AZD-7295 was well tolerated at repeated doses ofup to 700 mg daily. AZD-7295 shows potent antiviral activity ingenotype 1b patients. Genotype 1a and genotype 3 patients showedno antiviral effects.
Originator
Approval Year
Sample Use Guides
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:35:46 GMT 2023
by
admin
on
Sat Dec 16 10:35:46 GMT 2023
|
| Record UNII |
102MC1467J
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
102MC1467J
Created by
admin on Sat Dec 16 10:35:46 GMT 2023 , Edited by admin on Sat Dec 16 10:35:46 GMT 2023
|
PRIMARY | |||
|
929890-64-2
Created by
admin on Sat Dec 16 10:35:46 GMT 2023 , Edited by admin on Sat Dec 16 10:35:46 GMT 2023
|
PRIMARY | |||
|
DB12724
Created by
admin on Sat Dec 16 10:35:46 GMT 2023 , Edited by admin on Sat Dec 16 10:35:46 GMT 2023
|
PRIMARY | |||
|
57339445
Created by
admin on Sat Dec 16 10:35:46 GMT 2023 , Edited by admin on Sat Dec 16 10:35:46 GMT 2023
|
PRIMARY | |||
|
AZD-7295
Created by
admin on Sat Dec 16 10:35:46 GMT 2023 , Edited by admin on Sat Dec 16 10:35:46 GMT 2023
|
PRIMARY | Official Title:A Randomised, DB, PC Study to Determine the PK, Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of AZD7295 in Otherwise Healthy Male and Female Hepatitis C Carriers With Compensated Liver DiseasePurpose:PK, safety study of AZD7295 in HCV carriers |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Summary: This is a pharmacokinetics (PK) and safety study of AZD7295 in healthy volunteers.
Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment.
|
||
|
ACTIVE MOIETY |
Originator: Arrow Therapeutics; Class: Antiviral; Mechanism of Action: Hepatitis C virus NS 5 protein inhibitor; Highest Development Phase: Discontinued for Hepatitis C; Most Recent Events: 27 Jan 2011 Discontinued - Phase-II for Hepatitis C in United Kingdom (PO), 27 Jan 2011 Discontinued - Phase-I for Hepatitis C in Japan (PO), 27 Jan 2011 Discontinued - Phase-I for Hepatitis C in New Zealand (PO)
|
